Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Trial of SB-509 in Diabetic Neuropathy

_{//health-fitness.news-articles.net/content/2011/ .. e-2b-trial-of-sb-509-in-diabetic-neuropathy.html}
^{Published in Health and Fitness on Friday, September 30th 2011 at 19:41 GMT by Market Wire}  

Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b... -- RICHMOND, Calif., Sept. 30, 2011 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about SGMO

Teleconference and Webcast to be held at 8:30 am ET, Monday, October 3, 2011

RICHMOND, Calif., Sept. 30, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: [ SGMO ]) today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial (SB-509-901) from its ZFP Therapeutic® program to develop SB-509 as a treatment for diabetic neuropathy.  A press release summarizing the data from the trial will be issued at 7:00 am ET on Monday prior to this call.

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The passcode for the call is 15507481.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations [ http://investor.sangamo.com/events.cfm ]. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 11:30 am ET on October 3, 2011 to midnight ET on October 10, 2011. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406 respectively. The conference ID number for the replay is 15507481.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic® development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy. Sangamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at [ www.sangamo.com ].

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.

RELATED LINKS
[ http://www.sangamo.com ]